cagrilintide semaglutide cagrisema phase 3 results 2024 2025 RESEARCH ARTICLE: Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 @SubodhVermaMD https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.125.26055 Cagrilintide is an amylin analogue

Constantly thinking about when I could eat again

La aritmtica de la jeringa U-100 y los criterios de parada.

Medical weight loss with tirzepatide in Toledo, OH

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

Three new studies suggest GLP-1 drugs may reduce cancer risk and improve outcomes.